메뉴 건너뛰기




Volumn 43, Issue 1, 2009, Pages 9-18

Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia

Author keywords

Anticoagulation; Argatroban; Heparin induced thrombocytopenia; Nomogram

Indexed keywords

ARGATROBAN; HEPARIN; ANTICOAGULANT AGENT; PIPECOLIC ACID DERIVATIVE;

EID: 58549089194     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L213     Document Type: Article
Times cited : (23)

References (42)
  • 1
    • 0028923741 scopus 로고
    • Heparin-induced thrombocytopenia
    • Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995;89:431-9.
    • (1995) Br J Haematol , vol.89 , pp. 431-439
    • Chong, B.H.1
  • 2
    • 0029035681 scopus 로고
    • Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
    • Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
    • (1995) N Engl J Med , vol.332 , pp. 1330-1335
    • Warkentin, T.E.1    Levine, M.N.2    Hirsh, J.3
  • 4
    • 0024357798 scopus 로고
    • Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets
    • Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989;73:235-40.
    • (1989) Br J Haematol , vol.73 , pp. 235-240
    • Chong, B.H.1    Fawaz, I.2    Chesterman, C.N.3    Berndt, M.C.4
  • 5
    • 0027971564 scopus 로고
    • Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
    • Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-9.
    • (1994) Blood , vol.84 , pp. 3691-3699
    • Warkentin, T.E.1    Hayward, C.P.2    Boshkov, L.K.3
  • 6
    • 0030281338 scopus 로고    scopus 로고
    • A 14-year study of heparin-induced thrombocytopenia
    • Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
    • (1996) Am J Med , vol.101 , pp. 502-507
    • Warkentin, T.E.1    Kelton, J.G.2
  • 8
    • 0030983928 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution
    • Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997;56:12-6.
    • (1997) Am J Hematol , vol.56 , pp. 12-16
    • Nand, S.1    Wong, W.2    Yuen, B.3    Yetter, A.4    Schmulbach, E.5    Gross Fisher, S.6
  • 9
    • 0033029056 scopus 로고    scopus 로고
    • Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
    • Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-35.
    • (1999) Am J Med , vol.106 , pp. 629-635
    • Wallis, D.E.1    Workman, D.L.2    Lewis, B.E.3    Steen, L.4    Pifarre, R.5    Moran, J.F.6
  • 10
    • 0345369740 scopus 로고    scopus 로고
    • Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
    • for the HIT investigators group
    • Greinacher A, Volpel H, Janssens U, et al., for the HIT investigators group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
    • (1999) Circulation , vol.99 , pp. 73-80
    • Greinacher, A.1    Volpel, H.2    Janssens, U.3
  • 11
    • 0027442550 scopus 로고
    • Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaron (Org 10172)
    • Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaron (Org 10172). Thromb Haemost 1993;70:554-61.
    • (1993) Thromb Haemost , vol.70 , pp. 554-561
    • Magnani, H.N.1
  • 12
    • 0033543081 scopus 로고    scopus 로고
    • Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
    • for the Heparin-Associated Thrombocytopenia Study (HAT) investigators
    • Greinacher A, Janssens U, Berg G, et al., for the Heparin-Associated Thrombocytopenia Study (HAT) investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-93.
    • (1999) Circulation , vol.100 , pp. 587-593
    • Greinacher, A.1    Janssens, U.2    Berg, G.3
  • 13
    • 0026009696 scopus 로고
    • Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia
    • Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194-7.
    • (1991) Blood , vol.78 , pp. 2194-2197
    • Demers, C.1    Ginsberg, J.S.2    Brill-Edwards, P.3
  • 14
    • 0021262284 scopus 로고
    • Heparin-induced thrombocytopenia
    • King D, Kelton JG. Heparin-induced thrombocytopenia. Ann Intern Med 1984;100:535-40.
    • (1984) Ann Intern Med , vol.100 , pp. 535-540
    • King, D.1    Kelton, J.G.2
  • 15
    • 0022362993 scopus 로고
    • Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216)
    • Leroy J, Leclerc MH, Delahousse B, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216). Semin Thromb Hemost 1985;11:326-9.
    • (1985) Semin Thromb Hemost , vol.11 , pp. 326-329
    • Leroy, J.1    Leclerc, M.H.2    Delahousse, B.3
  • 16
    • 45949103154 scopus 로고    scopus 로고
    • American College of Chest Physicians; treatment and prevention of heparin-induced thrombocytopenia: ACCP evidence-based clinical practice guidelines
    • Warkentin TE, Greinacher A, Koster A, Lincoff AM. American College of Chest Physicians; treatment and prevention of heparin-induced thrombocytopenia: ACCP evidence-based clinical practice guidelines. Chest 2008;133(suppl 6):340S-80S.
    • (2008) Chest , vol.133 , Issue.SUPPL. 6
    • Warkentin, T.E.1    Greinacher, A.2    Koster, A.3    Lincoff, A.M.4
  • 17
    • 0035836541 scopus 로고    scopus 로고
    • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
    • Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.
    • (2001) Circulation , vol.103 , pp. 1838-1843
    • Lewis, B.E.1    Wallis, D.E.2    Berkowitz, S.D.3
  • 20
    • 0034049121 scopus 로고    scopus 로고
    • The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
    • Swan SK, Hursting M. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.
    • (2000) Pharmacotherapy , vol.20 , pp. 318-329
    • Swan, S.K.1    Hursting, M.2
  • 21
    • 0037765191 scopus 로고    scopus 로고
    • Argatroban dosing in patients with heparin-induced thrombocytopenia
    • DOI 10.1345/aph.1C443
    • Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:970-5. DOI 10.1345/aph.1C443
    • (2003) Ann Pharmacother , vol.37 , pp. 970-975
    • Verme-Gibboney, C.N.1    Hursting, M.J.2
  • 22
    • 0033937140 scopus 로고    scopus 로고
    • Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects
    • Swan SK, St. Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20:756-70.
    • (2000) Pharmacotherapy , vol.20 , pp. 756-770
    • Swan, S.K.1    St. Peter, J.V.2    Lambrecht, L.J.3    Hursting, M.J.4
  • 23
  • 24
    • 0022980224 scopus 로고
    • Pharmacokinetic studies of argipidine (MD -805) - protein binding and blood cell binding] Japanese
    • Tatsuno J, Komatsu T, Iida S. [Pharmacokinetic studies of argipidine (MD -805) - protein binding and blood cell binding] Japanese. Jpn Pharmacol Ther 1986;14(suppl 5):243-9.
    • (1986) Jpn Pharmacol Ther , vol.14 , Issue.SUPPL. 5 , pp. 243-249
    • Tatsuno, J.1    Komatsu, T.2    Iida, S.3
  • 25
    • 0037407491 scopus 로고    scopus 로고
    • Excessive argatroban anticoagulation for heparin-induced thrombocytopenia
    • DOI 10.1345/aph.1C187
    • Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652-4. DOI 10.1345/aph.1C187
    • (2003) Ann Pharmacother , vol.37 , pp. 652-654
    • Reichert, M.G.1    MacGregor, D.A.2    Kincaid, E.H.3    Dolinski, S.Y.4
  • 26
    • 0041422394 scopus 로고    scopus 로고
    • Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD
    • DOI 10.1345/aph.1D010
    • Dager WE, White RH. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. Ann Pharmacother 2003;37:1232-6. DOI 10.1345/aph.1D010
    • (2003) Ann Pharmacother , vol.37 , pp. 1232-1236
    • Dager, W.E.1    White, R.H.2
  • 27
    • 1542346478 scopus 로고    scopus 로고
    • Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction
    • Williamson DR, Boulander I, Tardif M, Albert M, Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24:409-14.
    • (2004) Pharmacotherapy , vol.24 , pp. 409-414
    • Williamson, D.R.1    Boulander, I.2    Tardif, M.3    Albert, M.4    Gregoire, G.5
  • 28
    • 18844400887 scopus 로고    scopus 로고
    • Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer
    • Epub 10 May, DOI 10.1345/aph.1G020
    • Kubiak DW, Szumita PM, Fanikos JR. Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother 2005;39:1119-23. Epub 10 May 2005. DOI 10.1345/aph.1G020
    • (2005) Ann Pharmacother 2005 , vol.39 , pp. 1119-1123
    • Kubiak, D.W.1    Szumita, P.M.2    Fanikos, J.R.3
  • 29
    • 41149173180 scopus 로고    scopus 로고
    • Reduced argatroban doses after coronary artery bypass graft surgery
    • Epub 26 Feb, DOI 10.1345/aph.1K434
    • Hoffman WD, Czyz Y, McCollum DA, Hursting MJ. Reduced argatroban doses after coronary artery bypass graft surgery. Ann Pharmacother 2008;42:309-16. Epub 26 Feb 2008. DOI 10.1345/aph.1K434
    • (2008) Ann Pharmacother 2008 , vol.42 , pp. 309-316
    • Hoffman, W.D.1    Czyz, Y.2    McCollum, D.A.3    Hursting, M.J.4
  • 30
    • 85069138737 scopus 로고    scopus 로고
    • Data on file. NDA submission, integrated summary of safety, Section 8, Table 8, demography of patients who participated in open-labeled studies. Includes Studies ARG-216m 240, 310, 911, 915. Texas Biotechnology Corporation, Houston, TX. Philadelphia, PA: GSK Pharmaceuticals.
    • Data on file. NDA submission, integrated summary of safety, Section 8, Table 8, demography of patients who participated in open-labeled studies. Includes Studies ARG-216m 240, 310, 911, 915. Texas Biotechnology Corporation, Houston, TX. Philadelphia, PA: GSK Pharmaceuticals.
  • 31
    • 34447620068 scopus 로고    scopus 로고
    • Argatroban anticoagulation in obese versus nonobese patients: Implications for treating heparin-induced thrombocytopenia
    • Rice L, Hursting MJ, Baillie GM, McCollum DA. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol 2007;47:1028-34.
    • (2007) J Clin Pharmacol , vol.47 , pp. 1028-1034
    • Rice, L.1    Hursting, M.J.2    Baillie, G.M.3    McCollum, D.A.4
  • 32
    • 0023003183 scopus 로고
    • Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
    • Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
    • (1986) N Engl J Med , vol.315 , pp. 1109-1114
    • Hull, R.D.1    Raskob, G.E.2    Hirsh, J.3
  • 33
    • 0019196280 scopus 로고
    • Heparin therapy for deep venous thrombosis
    • Kashtan J, Conti S, Blaisdell FW. Heparin therapy for deep venous thrombosis. Am J Surg 1980;140:836-40.
    • (1980) Am J Surg , vol.140 , pp. 836-840
    • Kashtan, J.1    Conti, S.2    Blaisdell, F.W.3
  • 34
    • 0014592649 scopus 로고
    • Assessment of anticoagulant treatment of venous thromboembolism
    • Coon WW, Willis PW 3rd, Symons MJ. Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg 1969;170:559-68.
    • (1969) Ann Surg , vol.170 , pp. 559-568
    • Coon, W.W.1    Willis 3rd, P.W.2    Symons, M.J.3
  • 35
    • 0015514101 scopus 로고
    • A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time
    • Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7.
    • (1972) N Engl J Med , vol.287 , pp. 324-327
    • Basu, D.1    Gallus, A.2    Hirsh, J.3    Cade, J.4
  • 37
    • 0024153910 scopus 로고
    • Thrombolyse intraveineuse dans l'infarctus du myocarde: Influence de la qualite de l'anticoagulation sur le taux de recidives precoces d'angor ou d'infarctus.
    • Camilleri JF, Bonnet JL, Bouvier JL, et al. Thrombolyse intraveineuse dans l'infarctus du myocarde: influence de la qualite de l'anticoagulation sur le taux de recidives precoces d'angor ou d'infarctus. Arch Mal Coeur 1988;81:1037-41.
    • (1988) Arch Mal Coeur , vol.81 , pp. 1037-1041
    • Camilleri, J.F.1    Bonnet, J.L.2    Bouvier, J.L.3
  • 38
    • 0038285887 scopus 로고    scopus 로고
    • Argatroban anticoagulation in patients with heparin-induced thrombocytopenia
    • for the Argatroban-915 Investigators
    • Lewis BE, Wallis DE, Leya F, for the Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-56.
    • (2003) Arch Intern Med , vol.163 , pp. 1849-1856
    • Lewis, B.E.1    Wallis, D.E.2    Leya, F.3
  • 39
    • 0017749446 scopus 로고
    • Control and complications of intermittent heparin therapy
    • Norman CS, Provan JL. Control and complications of intermittent heparin therapy. Surg Gynecol Obstet 1977;145:338-42.
    • (1977) Surg Gynecol Obstet , vol.145 , pp. 338-342
    • Norman, C.S.1    Provan, J.L.2
  • 40
    • 0023614407 scopus 로고
    • Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
    • Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13.
    • (1987) Am J Med , vol.82 , pp. 703-713
    • Landefeld, C.S.1    Cook, E.F.2    Flatley, M.3    Weisberg, M.4    Goldman, L.5
  • 41
    • 0026652032 scopus 로고
    • Optimal therapeutic level of heparin therapy in patients with venous thromboembolism
    • Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thromboembolism. Arch Intern Med 1992;152:1589-95.
    • (1992) Arch Intern Med , vol.152 , pp. 1589-1595
    • Hull, R.D.1    Raskob, G.E.2    Rosenbloom, D.3
  • 42
    • 0020264027 scopus 로고
    • A comparison of high-dose versus conventional-dose heparin therapy for deep vein thrombosis
    • Conti S, Daschbach M, Blaisdell FW. A comparison of high-dose versus conventional-dose heparin therapy for deep vein thrombosis. Surgery 1982;92:972-7.
    • (1982) Surgery , vol.92 , pp. 972-977
    • Conti, S.1    Daschbach, M.2    Blaisdell, F.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.